Breakthrough in Wellness

Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy

Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has been granted divisional patent approval by the China National Intellectual Property Administration.

The divisional patent approval, previously announced, grants Clearmind a broader claim than patent application. Allowed claims directed to using a primary amine aminoindan compound to regulate a binge behavior. Covers primary amine aminoindan compounds besides 5-methoxy-2-aminoindan (MEAI), the company's innovative psychedelic molecule. This latest patent builds upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.

The granting of this latest patent establishes both the company's patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space. Clearmind’s IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted patents in major jurisdictions such as the US, Europe, China, and India.

"We are proud to receive once again recognition of our innovative treatment for binge behaviors. We believe that this approval is a major milestone and significantly expands our IP protection as a leader in psychedelic-derived therapeutics,” said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani. “In various pre-clinical studies, carried out during the past 2 years, MEAI has demonstrated its ability to regulate binge behaviors, addiction and other mental health disorders. We believe these strong results demonstrate the significant potential of the MEAI molecule for various indications.”